CRISPR-Cas9

Lonza

Vertex adds CDMO Lonza to Casgevy production network

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain.

Fraiser Kansteiner Sep 24, 2024 9:41am

Rainbow colored molecules of DNA

Vertex, bluebird SCD gene therapies can cost $1.9M: ICER

Apr 13, 2023 11:33am

germ line gene editing DNA pass down family tree inherit

Vertex teases launch plans for first CRISPR gene editing therapy

Feb 8, 2023 2:55pm